Patients with mild Alzheimer’s disease should have access to drugs, says draft NICE guidanceBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5562 (Published 06 October 2010) Cite this as: BMJ 2010;341:c5562
- Zosia Kmietowicz
Patients with mild forms of Alzheimer’s disease should have access to three drugs previously reserved for people with more serious forms of the disease, says the National Institute for Health and Clinical Excellence (NICE).
In draft guidance for England and Wales NICE is proposing that the use of three acetylcholinesterase inhibitors—donepezil (marketed as Aricept), galantamine (Reminyl), and rivastigmine (Exelon)—should be extended to patients with mild Alzheimer’s disease. At the moment the drugs are reserved for those with moderate disease. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial